AH 7614
AH 7614 性质
| 熔点 | 196-197 °C(Solv: ethanol (64-17-5); 1,4-dioxane (123-91-1)) |
|---|---|
| 沸点 | 505.9±60.0 °C(Predicted) |
| 密度 | 1.37±0.1 g/cm3(Predicted) |
| 储存条件 | -20°C (des.) |
| 溶解度 | 溶于DMSO（最高50mg/ml）或乙醇（升温最高8mg/ml）。 |
| 形态 | 固体 |
| 酸度系数(pKa) | 10.33±0.20(Predicted) |
| 颜色 | 米白色 |
| 稳定性 | 可在-20°下的DMSO或乙醇溶液保存长达1个月。 |
| InChI | InChI=1S/C20H17NO3S/c1-14-10-12-15(13-11-14)25(22,23)21-20-16-6-2-4-8-18(16)24-19-9-5-3-7-17(19)20/h2-13,20-21H,1H3 |
| InChIKey | OZCQEUZTOAAWDK-UHFFFAOYSA-N |
| SMILES | C1(S(NC2C3=C(C=CC=C3)OC3=C2C=CC=C3)(=O)=O)=CC=C(C)C=C1 |
AH 7614 用途与合成方法
pIC50: 7.1 (human FFA4)
AH-7614 (compound 39) (0.063-1 μM) blocks intracellular Ca
2+
response induced by both linoleic acid and FFAR4 agonist in FFA4 expressing U2OS cells.
AH-7614 (100 μM) abolishes the enhancement in glucose-stimulated insulin secretion by GSK137647A in NCI-H716 cells.
AH-7614 (0.001-10 μM; 15 min) blocks TUG-891-mediated internalization of FFA4 from the cell surface (pIC
50
=7.70).
AH-7614 (10 μM; 30 min) blocks agonist-induced elevation of intracellular inositol monophosphates and phosphorylation of FFA4.
AH7614 (50 μg; intratumoral injection once every 4 d for 20 d) reduces the tumor growth in mice.
AH7614 (50 μg; intratumoral injection one day prior to epirubicin injection) enhances cancer cell sensitivity to the chemotherapy and inhibit tumor progression by blocking GPR120 signaling in combination with Epirubicin.
AH 7614 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025-12-22 | HY-19996 | 6326-06-3 | 1 mg | 280 | |
| 2025-12-22 | HY-19996 | AH 7614 | 6326-06-3 | 5mg | 700 |
